Dynavax Reaffirms Full Year 2024 Financial Guidance; Expects Cash & Equivalents To Be Higher Y/Y At December 31, 2024
Portfolio Pulse from Benzinga Newsdesk
Dynavax has reaffirmed its full-year 2024 financial guidance, expecting an increase in cash and equivalents year-over-year by December 31, 2024. The company anticipates HEPLISAV-B net product revenue to be between $265 million and $280 million, which includes about $3 million from ex-U.S. sales through a commercialization partnership in Germany. Additionally, the HEPLISAV-B gross margin is projected to be around 80%.
May 08, 2024 | 8:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dynavax reaffirms its 2024 financial guidance, projecting an increase in cash and equivalents and expecting HEPLISAV-B revenue between $265M-$280M with a gross margin of 80%.
Reaffirming financial guidance, especially with an anticipated increase in cash and equivalents, is a positive signal to investors, indicating stability and growth potential. The specific revenue forecast for HEPLISAV-B, including details on international sales through a partnership in Germany, further supports the positive outlook. The high gross margin projection for HEPLISAV-B underscores the product's profitability, which is likely to be viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100